IDO1 and neoplasm: Finally, trials to evaluate the potential of targeting the metabolic crosstalk between the tumor and the stroma should be designed more carefully and based on a deeper in vivo understanding if we wish to avoid a stinging failure like that of IDO inhibitors and be able to propose efficient combination strategies to bypass immune checkpoint inhibitor resistance.